Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT · References

References

CC BY 4.0 · NIHR Journals Library · approximately 11 min read

  1. Diabetes.co.uk. Diabetes Prevalence. URL: www.diabetes.co.uk/diabetes-prevalence.html (accessed July 2018).
  2. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227–39. 10.1056/NEJMra100507322455417
  3. Abbate M, Cravedi P, Iliev I, Remuzzi G, Ruggenenti P. Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives. Curr Diabetes Rev 2011;7:190–200. 10.2174/15733991179584316821438851
  4. Scanlon PH. Why do patients still require surgery for the late complications of Proliferative Diabetic Retinopathy? Eye 2010;24:435–40. 10.1038/eye.2009.32020057509
  5. Sivaprasad S, Gupta B, Gulliford MC, Dodhia H, Mohamed M, Nagi D, Evans JR. Ethnic variations in the prevalence of diabetic retinopathy in people with diabetes attending screening in the United Kingdom (DRIVE UK). PLOS ONE 2012;7:e32182. 10.1371/journal.pone.003218222412857
  6. Sivaprasad S, Gupta B, Gulliford MC, Dodhia H, Mann S, Nagi D, Evans J. Ethnic variation in the prevalence of visual impairment in people attending diabetic retinopathy screening in the United Kingdom (DRIVE UK). PLOS ONE 2012;7:e39608. 10.1371/journal.pone.003960822761840
  7. Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev 2011;7:291–304. 10.2174/15733991179741562021916837
  8. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98(Suppl. 5):766–85. 10.1016/S0161-6420(13)38011-72062512
  9. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383–96. 10.1016/0002-9394(76)90292-0944535
  10. Stefánsson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 2006;51:364–80. 10.1016/j.survophthal.2006.04.00516818083
  11. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122–35. 10.1016/S0002-9394(03)00219-812834680
  12. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. Eye 1999;13:151–9. 10.1038/eye.1999.4210450373
  13. Flynn HW Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL 3rd. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1992;99:1351–7. 10.1016/S0161-6420(92)31779-81407968
  14. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009;127:132–40. 10.1001/archophthalmol.2008.56519204228
  15. Mackie SW, Walsh G. Contrast and glare sensitivity in diabetic patients with and without pan-retinal photocoagulation. Ophthalmic Physiol Opt 1998;18:173–81. 10.1016/S0275-5408(97)00083-59692039
  16. Subash M, Comyn O, Samy A, Qatarneh D, Antonakis S, Mehat M, et al. The effect of multispot laserpanretinal photocoagulation on retinal sensitivity and driving eligibility in patients with diabetic retinopathy. JAMA Ophthalmol 2016;134:666–72. 10.1001/jamaophthalmol.2016.062927077924
  17. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399–411. 10.1016/j.ophtha.2012.04.01522578446
  18. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66–71. 10.1001/archopht.1996.011001300620108540853
  19. Lange CAK, Stavrakas P, Luhmann UFO, de Silva DJ, Ali RR, Gregor ZJ, Bainbridge JWB. Intraocular oxygen distribution in advanced proliferative diabetic retinopathy. Am J Ophthalmol 2011;152:406–12. 10.1016/j.ajo.2011.02.01421723532
  20. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1:182–93.8529097
  21. Miller JW, Adamis AP, Shima DT, D’Amore PA, Moulton RS, O’Reilly MS, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574–84.7521577
  22. Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside. Ophthalmology 2016;123:S78–S88. 10.1016/j.ophtha.2016.04.05627664289
  23. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–7. 10.1056/NEJM1994120133122037526212
  24. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457–61. 10.1073/pnas.92.23.104577479819
  25. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012;130:1145–52. 10.1001/archophthalmol.2012.104322965590
  26. Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol 2011;89:405–11. 10.1111/j.1755-3768.2010.02079.x21294854
  27. Weidle UH, Schneider B, Georges G, Brinkmann U. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics 2012;9:357–72.23162075
  28. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171–85. 10.1007/s10456-011-9249-622302382
  29. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193–201. 10.1016/j.ophtha.2013.08.01124084500
  30. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016;123:1351–9. 10.1016/j.ophtha.2016.02.02226935357
  31. Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015;122:2044–52. 10.1016/j.ophtha.2015.06.01726198808
  32. National Institute for Health and Care Excellence. Type 2 Diabetes in Adults: Management. NICE Guidelines NG28. London: National Institute for Health and Care Excellence. URL: www.nice.org.uk/guidance/ng28 (accessed 10 August 2018).
  33. Sivaprasad S, Prevost AT, Bainbridge J, Edwards RT, Hopkins D, Kelly J, et al. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial. BMJ Open 2015;5:e008405. 10.1136/bmjopen-2015-008405
  34. Rosser DA, Cousens SN, Murdoch IE, Fitzke FW, Laidlaw DA. How sensitive to clinical change are ETDRS logMAR visual acuity measurements? Invest Ophthalmol Vis Sci 2003;44:3278–81. 10.1167/iovs.02-110012882770
  35. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91–6. 10.1016/0002-9394(82)90197-07091289
  36. Elliott DB, Bullimore MA, Bailey IA. Improving the reliability of the Pelli–Robson contrast sensitivity test. Clin Vis Sci 1991;6:471–5.
  37. Esterman B. Functional scoring of the binocular field. Ophthalmology 1982;89:1226–34. 10.1016/S0161-6420(82)34647-37155532
  38. Brose LS, Bradley C. Psychometric development of the retinopathy treatment satisfaction questionnaire (RetTSQ). Psychol Health Med 2009;14:740–54. 10.1080/1354850090343148520183546
  39. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050–8. 10.1001/archopht.119.7.105011448327
  40. Brose LS, Bradley C. Psychometric development of the individualized Retinopathy-Dependent Quality of Life Questionnaire (RetDQoL). Value Health 2010;13:119–27. 10.1111/j.1524-4733.2009.00589.x19695003
  41. Janssen MF, Birnie E, Bonsel GJ. Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods. Qual Life Res 2008;17:463–73. 10.1007/s11136-008-9318-518320352
  42. Al-Janabi H, Peters TJ, Brazier J, Bryan S, Flynn TN, Clemens S, et al. An investigation of the construct validity of the ICECAP-A capability measure. Qual Life Res 2013;22:1831–40. 10.1007/s11136-012-0293-523086535
  43. Great Britain. The Data Protection Act 1998. London: The Stationery Office; 1998.
  44. Macedo AF, Ramos PL, Hernandez-Moreno L, Cima J, Baptista AMG, Marques AP, et al. Visual and health outcomes, measured with the activity inventory and the EQ-5D, in visual impairment. Acta Ophthalmol 2017;95:e783–e791. 10.1111/aos.1343028371261
  45. Luo N, Wang X, Ang M, Finkelstein EA, Aung T, Wong TY, Lamoureux E. A vision ‘bolt-on’ item could increase the discriminatory power of the EQ-5D Index score. Value Health 2015;18:1037–42. 10.1016/j.jval.2015.08.00226686788
  46. Department of Health and Social Care. NHS Reference Costs 2015 to 2016. London: Department of Health and Social Care; 2016. URL: www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016 (accessed 18 June 2017).
  47. Joint Formulary Committee. British National Formulary. 72 ed. London: BMJ Group and Pharmaceutical Press; 2016.
  48. Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006;61:531–6. 10.1111/j.1398-9995.2006.01038.x16629780
  49. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991;98:786–806. 10.1016/S0161-6420(13)38012-92062513
  50. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106. 10.1136/bmj.308.6921.818298418
  51. CATT (Comparison of Age-related macular degeneration Treatments Trials) Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–908. 10.1056/NEJMoa110267321526923
  52. Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes 2016;7:333–41. 10.4239/wjd.v7.i16.33327625747
  53. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015;314:2137–46. 10.1001/jama.2015.1521726565927
  54. González VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol 2009;93:1474–8. 10.1136/bjo.2008.15566319692371
  55. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 1999;18:1905–42.10532877
  56. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med 2005;24:993–1007. 10.1002/sim.198115570623
  57. D’Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues – the encounters of academic consultants in statistics. Stat Med 2003;22:169–86. 10.1002/sim.142512520555
  58. White IR, Carpenter J, Horton NJ. Including all individuals is not enough: lessons for intention-to-treat analysis. Clin Trials 2012;9:396–407. 10.1177/174077451245009822752633
  59. Lesaffre E. Superiority, equivalence, and non-inferiority trials. Bull NYU Hosp Jt Dis 2008;66:150–4.18537788
  60. Garrett AD. Therapeutic equivalence: fallacies and falsification. Stat Med 2003;22:741–62. 10.1002/sim.136012587103
  61. Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol 2001;52:223–8. 10.1046/j.1365-2125.2001.01397-3.x11560553
  62. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:d40. 10.1136/bmj.d4021300711
  63. Burzykowski T, Carpenter J, Coens C, Evans D, France L, Kenward M, et al. Missing data: discussion points from the PSI missing data expert group. Pharm Stat 2010;9:288–97. 10.1002/pst.39119844946
  64. White IR, Kalaitzaki E, Thompson SG. Allowing for missing outcome data and incomplete uptake of randomised interventions, with application to an internet-based alcohol trial. Stat Med 2011;30:3192–207. 10.1002/sim.436021948462
  65. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19:1141–64. 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F10797513
  66. Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 2017;389:2193–203. 10.1016/S0140-6736(17)31193-528494920
  67. Ramu J, Chatziralli I, Yang Y, Menon G, Bailey C, Eckstein M, et al. Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema. Patient Prefer Adherence 2017;11:579–86. 10.2147/PPA.S13285928360511
  68. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Eff Resour Alloc 2013;11:6. 10.1186/1478-7547-11-623531194
  69. Ridyard CH, Hughes DA. Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. Value Health 2010;13:867–72. 10.1111/j.1524-4733.2010.00788.x20946187
  70. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Canterbury: Personal Social Services Research Unit (PSSRU), University of Kent; 2016.
  71. NHS Choices. Acupuncture on the NHS. URL: www.nhs.uk/conditions/Acupuncture/Pages/Introduction.aspx#NHS (accessed 18 June 2017).
  72. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford: Oxford University Press; 2007.
  73. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th edn. Oxford: Oxford University Press; 2015.
  74. Grewal I, Lewis J, Flynn T, Brown J, Bond J, Coast J. Developing attributes for a generic quality of life measure for older people: preferences or capabilities? Soc Sci Med 2006;62:1891–901. 10.1016/j.socscimed.2005.08.02316168542
  75. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96. 10.1002/hec.94415497198
  76. Laramée P, Wonderling D, Cahen DL, Dijkgraaf MG, Gouma DJ, Bruno MJ, Pereira SP. Trial-based cost-effectiveness analysis comparing surgical and endoscopic drainage in patients with obstructive chronic pancreatitis. BMJ Open 2013;3:e003676. 10.1136/bmjopen-2013-003676
  77. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736–41. 10.1136/bmj.316.7133.7369529408
  78. Hardarson SH, Harris A, Karlsson RA, Halldorsson GH, Kagemann L, Rechtman E, et al. Automatic retinal oximetry. Invest Ophthalmol Vis Sci 2006;47:5011–16. 10.1167/iovs.06-003917065521
  79. Hardarson SH, Gottfredsdottir MS, Halldorsson GH, Karlsson RA, Benediktsson JA, Eysteinsson T, et al. Glaucoma filtration surgery and retinal oxygen saturation. Invest Ophthalmol Vis Sci 2009;50:5247–50. 10.1167/iovs.08-311719494205
  80. Nicholson L, Vazquez-Alfageme C, Ramu J, Triantafyllopoulou I, Patrao NV, Muwas M, et al. Validation of concentric rings method as a topographic measure of retinal nonperfusion in ultra-widefield fluorescein angiography. Am J Ophthalmol 2015;160:1217–25.e2. 10.1016/j.ajo.2015.09.00326384165
  81. Nicholson L, Vazquez-Alfageme C, Clemo M, Luo Y, Hykin PG, Bainbridge JW, Sivaprasad S. Quantifying retinal area in ultra-widefield imaging using a 3-dimensional (3-D) printed eye model. Ophthalmol Retina 2017;2:65–71. 10.1016/j.oret.2017.03.011
  82. Nicholson L, Crosby-Nwaobi R, Vasconcelos JC, Prevost AT, Ramu J, Riddell A, et al. Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy. Invest Ophthalmol Vis Sci 2018;59:4277–84. 10.116/iovs.17-23509
  83. Driver and Vehicle Licensing Agency. Visual Disorders: Assessing Fitness to Drive. Swansea: Driver and Vehicle Licensing Agency. URL: www.gov.uk/guidance/visual-disorders-assessing-fitness-to-drive (accessed 15 April 2017).
  84. Muqit MM, Wakely L, Stanga PE, Henson DB, Ghanchi FD. Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy. Eye 2010;24:1136–42. 10.1038/eye.2009.30820019760
  85. Muqit MM, Young LB, McKenzie R, John B, Marcellino GR, Henson DB, et al. Pilot randomised clinical trial of Pascal TargETEd Retinal versus variable fluence PANretinal 20 ms laser in diabetic retinopathy: PETER PAN study. Br J Ophthalmol 2013;97:220–7. 10.1136/bjophthalmol-2012-30218923178855
  86. Guduru A, Martz TG, Waters A, Kshirsagar AV, Garg S. Oxygen saturation of retinal vessels in all stages of diabetic retinopathy and correlation to ultra-wide field fluorescein angiography. Invest Ophthalmol Vis Sci 2016;57:5278–84. 10.1167/iovs.16-2019027723894
  87. Jørgensen CM, Bek T. Lack of differences in the regional variation of oxygen saturation in larger retinal vessels in diabetic maculopathy and proliferative diabetic retinopathy. Br J Ophthalmol 2017;101:752–7. 10.1136/bjophthalmol-2016-30889427553678
  88. Hutton DW, Stein JD, Bressler NM, Jampol LM, Browning D, Glassman AR, Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy: secondary analysis from a diabetic retinopathy clinical research network randomized clinical trial. JAMA Ophthalmol 2017;135:576–84. 10.1001/jamaophthalmol.2017.083728492920
  89. Brown MM, Brown GC, Sharma S, Busbee B. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology 2003;110:1076–81. 10.1016/S0161-6420(03)00254-912799229
  90. NHS Digital. Prescription Cost Analysis, England – 2016. Leads: NHS Digital; 2017. URL: https://digital.nhs.uk/catalogue/PUB23631 (accessed 15 April 2017).
← ConclusionAcknowledgements →

Attribution. Sobha Sivaprasad; Philip Hykin; A Toby Prevost; Joana Vasconcelos; Amy Riddell; Jayashree Ramu et al. (2018). Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT. NIHR Journals Library. Copyright © Queen’s Printer and Controller of HMSO 2018. This work was produced by Sivaprasad et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Licensed under CC BY 4.0. NCBI Bookshelf NBK531673. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support